AstraZeneca (AZN) Sells the rights of Two drugs to Cheplapharm for US$400 million

3 min read | November 03, 2020 05:36 PM AEDT | By Team Kalkine Media

AstraZeneca (AZN) Sells the rights of Two drugs to Cheplapharm for US$400 million

About AstraZeneca Inc

Global, science-led biopharmaceutical player AstraZeneca is engaged in the development and commercialisation of prescription medicines for the treatment in the fields of- Respiratory & Immunology, Cardiovascular, Oncology, and Renal & Metabolism.

AstraZeneca is one of the top pharmaceutical manufacturers with a potential COVID-19 vaccine under late-stage clinical development.

AstraZeneca’s Agreement with Cheplapharm for US$400 million

On 30 October 2020, AstraZeneca updated the market that the Company had signed an agreement to sell the commercial rights of its two hypertension drugs Atacand and Atacand Plus to Cheplapharm. With this agreement, Atacand is to be divested to Cheplapharm in over seventy nations across the world.

AstraZeneca said that this agreement provides support to the strategy to focus on new drugs in main therapy areas.

Executive Vice President, BioPharmaceuticals Business Unit of AstraZeneca, Ruud Dobber commented-

AstraZeneca will continue manufacturing along with supply of both the drugs. The Company would also persist to commercialise the medicine during the transition period of three years. The Company also mentioned that this agreement covers more than 70 nations.

Atacand (candesartan cilexetil) drug is approved for heart failure (HF) and hypertension treatment. The other drug Atacand Plus is a combination of hydrochlorothiazide and candesartan cilexetil and approved for the treatment of hypertension.

The agreement is anticipated to be completed during the fourth quarter of 2020, and Cheplapharm will pay a total of US$400 million to AstraZeneca in non-contingent consideration.

Additionally, AstraZeneca mentioned that the divestment would not have any impact on the Company’s financial guidance for 2020. The amount would be paid in cash and the proceeds are to be utilised for general corporate purposes.

Moreover, AstraZeneca is one of the top contenders in the list of developing a potential COVID-19 vaccine, which is under late-stage clinical development. Lately, the Company stated that the Medicines and Healthcare Products Regulatory Agency (MHRA) commenced an accelerated review of its COVID-19 vaccine, paving the way for its early launch.

On 2 November 2020, AstraZeneca’s share price was at US$50.62 on NASDAQ, up by 0.92% from its last close.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.